• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Principal Accounting Officer Kondo Chris sold $933,955 worth of shares (4,486 units at $208.19), decreasing direct ownership by 22% to 15,533 units (SEC Form 4)

    5/14/25 6:30:28 PM ET
    $AAPL
    Computer Manufacturing
    Technology
    Get the next $AAPL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    KONDO CHRIS

    (Last) (First) (Middle)
    ONE APPLE PARK WAY

    (Street)
    CUPERTINO CA 95014

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Apple Inc. [ AAPL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Principal Accounting Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/12/2025 S 4,486 D $208.1933 15,533 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    /s/ Sam Whittington, Attorney-in-Fact for Chris Kondo 05/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AAPL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AAPL

    DatePrice TargetRatingAnalyst
    6/4/2025Buy → Hold
    Needham
    5/2/2025$290.00 → $275.00Buy
    TD Cowen
    5/2/2025$217.00Buy → Neutral
    Rosenblatt
    5/2/2025$170.62Hold → Underperform
    Jefferies
    5/2/2025$260.00 → $245.00Buy
    Monness Crespi & Hardt
    4/30/2025$197.00 → $173.00Underweight
    Barclays
    4/30/2025$230.00 → $215.00Hold
    Loop Capital
    4/29/2025$220.00 → $235.00Overweight
    Morgan Stanley
    More analyst ratings

    $AAPL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 17, 2024 - FDA Roundup: September 17, 2024

      For Immediate Release: September 17, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a draft guidance, “Integrating Randomized Controlled Trials for Drug and Biological Products into Routine Clinical Practice,” which, when finalized, will support the conduct of randomized controlled trials with streamlined protocols a

      9/17/24 2:34:22 PM ET
      $AAPL
      Computer Manufacturing
      Technology
    • September 12, 2024 - FDA Authorizes First Over-the-Counter Hearing Aid Software

      For Immediate Release: September 12, 2024 Today, the U.S. Food and Drug Administration authorized the first over-the-counter (OTC) hearing aid software device, Hearing Aid Feature, intended to be used with compatible versions of the Apple AirPods Pro headphones. Once installed and customized to the user’s hearing needs, the Hearing Aid Feature enables compatible versions of the AirPods Pro to serve as an OTC hea

      9/12/24 10:58:17 AM ET
      $AAPL
      Computer Manufacturing
      Technology

    $AAPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Apple downgraded by Needham

      Needham downgraded Apple from Buy to Hold

      6/4/25 7:32:32 AM ET
      $AAPL
      Computer Manufacturing
      Technology
    • TD Cowen reiterated coverage on Apple with a new price target

      TD Cowen reiterated coverage of Apple with a rating of Buy and set a new price target of $275.00 from $290.00 previously

      5/2/25 8:26:19 AM ET
      $AAPL
      Computer Manufacturing
      Technology
    • Apple downgraded by Jefferies with a new price target

      Jefferies downgraded Apple from Hold to Underperform and set a new price target of $170.62

      5/2/25 8:06:00 AM ET
      $AAPL
      Computer Manufacturing
      Technology